1 - “Gut” to Be Important: The Microbiome and Its Role in Neutropenic Patients Undergoing Chemotherapy and Stem Cell Therapy

Wednesday, October 16, 2024

1:30 PM – 3:15 PM US PT

Location: 515 A

All relevant financial relationships have been mitigated.

CME Credits: Maximum of 1.75 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.75 hours of MOC Credit
CNE Credits: Maximum of 1.75 hours of ANCC Credit
ACPE Credits: ACPE 1.75 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 2 of PACE contact hours
CE Broker: Maximum of 2 CE broker credit hours

Moderator(s)

Murat Akova, Prof. (he/him/his)

Professor
Hacettepe University
Ankara, Ankara, Turkey
Maricar Malinis, MD (she/her/hers)

Associate Professor of Medicine
Section of Infectious Diseases
Vanderbilt University Medical Center, TN, United States

Faculty(s)

David Fredricks, MD (he/him/his)

Professor
Infectious Diseases
Fred Hutchinson Cancer Research Center; University of Washington
Seattle, WA, United States
Tobias Hohl, MD, PhD (he/him/his)

Chief, Infectious Disease Service Member, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY, United States
Robert Jenq, MD (he/him/his)

Professor
Department of Genomic Medicine, Division of Cancer Medicine
City of Hope National Medical Center, Duarte, CA, CA, United States

Disclosure(s):

Murat Akova, Prof.: No financial relationships to disclose

Maricar F. Malinis, MD: Moderna ( concluded): Advisor/Consultant; Paratek Pharmaceuticals, Inc.: Honoraria

David Fredricks, MD: Becton, Dickinson and Company (BD): Royalty (Ongoing)

Tobias Hohl, MD, PhD: No financial relationships to disclose

Robert Jenq, MD: LISCure Biosciences: Board Member (Ongoing); MaaT Pharma: Board Member (Ongoing); Postbiotics Plus Research LLC: Advisor/Consultant (Ongoing); Prolacta: Advisor/Consultant (Ongoing); Seres Therapeutics: Board Member (Ongoing), Stocks/Bonds (Private Company) (Ongoing)

Learning Objectives:

At the conclusion of this session, participants will be able to:

describe changes in gut microbiota in cancer patients;
recognize the role of various drugs and antibiotics on changes of gut microbiota;
Identify the relationship between mucin-degrading bacteria and fever in severely neutropenic patients;
explain the impact of gut microbiota on complications and outcomes in cancer patients.

Presentations:

1:30 PM – 2:05 PM US PT

The gut microbiota of cancer patients as predictor of complications and outcomes
Speaker: David Fredricks, MD (he/him/his) – Fred Hutchinson Cancer Research Center; University of Washington
2:05 PM – 2:40 PM US PT

The role of the mycobiome in hematopoietic cell transplantation outcomes
Speaker: Tobias Hohl, MD, PhD (he/him/his) – Memorial Sloan Kettering Cancer Center
2:40 PM – 3:15 PM US PT

Diet, mucus and microbiome in cancer-related neutropenic fever
Speaker: Robert Jenq, MD (he/him/his) – City of Hope National Medical Center, Duarte, CA